Reference 2019-589

REF:            2019-589

Subject:        Intra-vitreal vials/implants

    

 

Request:

Within your trust how many of the following intra-vitreal vials/implants have been used in the latest 4 months, if possible between May to August 2019; for the following eye conditions;

Wet Age Related Macular Degeneration (wAMD)

*Ranibizumab, Bevacizumab, Aflibercept, Fluocinolone, Dexamethasone.

 

Diabetic Macular Oedema (DMO)

* Ranibizumab, Bevacizumab, Aflibercept, Fluocinolone, Dexamethasone.

 

Retinal Vein Occlusion – Central or Branch (CRVO or BRVO)

*Ranibizumab, Bevacizumab, Aflibercept, Fluocinolone, Dexamethasone.

 

Other eg mCNV

*Ranibizumab, Bevacizumab, Aflibercept, Fluocinolone, Dexamethasone.

 

 

Response:

We can provide a response to the earlier FOI (http://www.boltonft.nhs.uk/reference-2019-583/)  but we are unable to break down by indication as request in this FOI, I will therefore only respond to the earlier FOI.